Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression

This article was originally published in The Pink Sheet Daily

Executive Summary

Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.

You may also be interested in...



Novo Nordisk’s Saxenda Initially Positioned For Private Patients In Europe

Obese patients who are severely ill with a high BMI and co-morbidities, and who are highly motivated to try a new therapy and willing to pay for it out-of-pocket, will be targeted for Saxenda.

CTI Finds Pixuvri’s Conditional Authorization Is Not Enough To Win NICE Approval

In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.

FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave

Timing of the study to be discussed at Dec. 7 advisory committee meeting.

Related Content

Topics

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel